MedTrace Logo

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

NCT00300196 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 311

Last updated 2010-01-12

No results posted yet for this study

Summary

The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.

Conditions

  • Stroke
  • Cerebral Ischemia
  • Brain Infarction

Interventions

BIOLOGICAL

Ancrod (Viprinex)

0.167 IU/kg/hr IV for 2-3 hours

DRUG

Placebo

0.6 mL/kg/hr

Sponsors & Collaborators

  • Neurobiological Technologies

    lead INDUSTRY

Principal Investigators

  • Warren Wasiewski, M.D. · Neurobiological Technologies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States
  • Australia
  • Austria
  • Czechia
  • Israel
  • New Zealand
  • Poland
  • Russia
  • Slovakia
  • South Africa
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300196 on ClinicalTrials.gov